Exact sciences corporation stock.

Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 16.9% so far this month. During the month of September, Exact Sciences Corp’s stock price has reached a high of $85.71 and a low of $69.26. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $29.27. Year to date, Exact ...In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.Nov 9, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...

View Exact Sciences Corporation EXAS investment & stock information. Get the latest Exact Sciences Corporation EXAS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Currently, Kevin T. Conroy occupies the position of Chairman, President & Chief Executive Officer at EXACT Sciences Corp. and President & Director at Genomic Health, Inc. (a subsidiary of EXACT Sciences Corp.). He is also on the board of 8 other companies. Kevin T. Conroy previously was Partner at McDermott Will & Emery LLP, Director at ...EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level …

Exact Sciences Corporation. 21 Feb, 2023, 16:05 ET. Reports record revenue, expects revenue of $2,265 -2,315 million and positive adjusted EBITDA for full year 2023. Fourth quarter and 2022 ...

Story continues. SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and ...Exact Sciences Corporation‘s EXAS shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a ...Exact Sciences Corp (NASDAQ:EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million.Exact Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Ultragenyx (RARE), a stock from the same industry, has gained 6.7%.Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023

15-May-2017 ... One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known ...

Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ...

Nov 17, 2023 · Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Tucson, Ariz. (February 1, 2023) - The PGA TOUR Champions, the Tucson Conquistadores, the First Tee Tucson, and Exact Sciences, the maker of Cologuard ®, announced today that the Madison, Wisconsin-based company will now be the presenting sponsor of the Cologuard Classic.The announcement also extends Cologuard's title …Nov 30, 2022 · Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Nov 30, 2023Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.

Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com. About Exact Sciences Corp.Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsMADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our Tests

Nov 1, 2023 · Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent.

10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the …Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ...

Nov 17, 2023 · Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

June 7, 2023 at 10:53 AM · 4 min read. Exact Sciences Corporation EXAS is well poised for growth in coming quarters, led by the continued strength across the Screening and Precision Oncology ...

Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsExact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session. ... Exact Sciences Corporation (EXAS) : Free Stock Analysis Report.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to …Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...Exact Sciences Co. (NASDAQ:EXAS) has garnered attention in the investment world, as Sanders Morris Harris LLC recently acquired a new position in the company during the second quarter of this year. The firm purchased 5,000 shares of Exact Sciences’ stock, with an approximate value of $467,000. This move by Sanders Morris Harris LLC indicates ...Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqSep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... 11-Feb-2020 ... Exact Sciences Announces Fourth-Quarter 2019 Results ; Net income (loss) per share—basic. $. 0.56 ; Net income (loss) per share—diluted. $. 0.54.

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PMWhirlpool makes Maytag appliances as of 2015. In 2005, the Whirlpool Corporation bought out Maytag for more than $2.7 million in cash, debt and stock. Whirlpool is the nation’s biggest appliance manufacturer.MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and …Instagram:https://instagram. who qualifies for a tfra accountbest option trading strategieswatch insurance costmint moble stock EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. draftkings predictionswalmart investment The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ... vanguard best money market fund Find the latest Exact Sciences Corporation (EXK.F) stock quote, history, news and other vital information to help you with your stock trading and investing."Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that …EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …